The legally binding text is the original French version
|
|
- Russell Garrison
- 5 years ago
- Views:
Transcription
1 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 28 March 2007 FACTANE 100 I.U. /ml, powder and solvent for solution for injection Box of ml vial (CIP: ) Box of 1 5 ml vial (CIP: ) Box of 1 10 ml vial (CIP: ) Applicant : LFB BIOMEDICAMENTS Human Coagulation Factor VIII List I Medicine for initial hospital prescription of six months (including blood transfusion organisations authorised to dispense medicinal products derived from the blood of patients treated). Issuance is restricted to pharmacies of healthcare organisations or blood transfusion organisations for patients treated therein. Date of Marketing Authorisation: 30 December, 1994 Revision (extension of indication): 4 July, 2006 Reason for request: Inclusion on the list of medicines for use by hospitals in the extension of indication: Human coagulation factor VIII is indicated for the treatment of inhibitors by immune tolerance induction (ITI). Health Technology Assessment Division 1
2 1. CHARACTERISTICS OF THE MEDICINAL PRODUCT 1.1. Active ingredient Human Coagulation Factor VIII 1.2. Indications Human coagulation factor VIII is indicated for the treatment and prevention of haemorrhagic episodes and during surgery due to factor VIII deficiency (haemophilia A) in previously treated or untreated patients, without any inhibitors against factor VIII. Treatment may be continued in patients who develop factor VIII inhibitors (neutralising antibodies) at levels less than 5 Bethesda units (BU) if clinical response persists and circulating factor VIII levels increase. Human coagulation factor VIII is indicated for the treatment of inhibitors by immune tolerance induction. FACTANE does not contain von Willebrand factor in effective quantities and is therefore not indicated in von Willebrand disease Dosage (see SPC) Treatment of inhibitors by immune tolerance induction (ITI) Immune tolerance treatment should be initiated and conducted by a centre with experience in the treatment of patients with haemophilia A. Table 1 Immune tolerance induction (ITI) Initiation Levels 0.6 to 5 BU Levels > 5 BU DOSES* 50 IU/kg/day 3 times per week to 100 IU/kg/day every day IU/kg/day 3 times per week to 100 to 300 IU/kg/day every day Administration procedures ITI should be initiated as soon as possible After disappearance of the inhibitors, resumption of normal recovery and half-life 100 IU/kg/day then 50 IU/kg/day then 50 IU/kg every other day then prophylactic treatment (* indicative treatment to be adapted according to biological controls) in monthly increments 3 times per week for at least 1 year Clinical data obtained during retrospective studies in 6 patients demonstrated that inhibitors had completely disappeared under immune tolerance induction in 5 of them after several years of follow-up and had partially disappeared in the sixth patient. 2
3 2. SIMILAR MEDICINAL PRODUCTS 2.1. ATC Classification 2006 B: BLOOD AND BLOOD FORMING ORGANS B02: ANTIHAEMORRHAGICS B02B: VITAMIN K AND OTHER HAEMOSTATICS B02BD: BLOOD COAGULATION FACTORS B02BD02: HUMAN COAGULATION FACTOR VIII 2.2. Medicines in the same therapeutic category Plasma-derived factor VIII: Recombinant Factor VIII: OCTANATE, MONOCLATE P, HEMOFIL-M (no longer marketed). HELIXATE NEXGEN KOGENATE BAYER RECOMBINATE REFACTO ADVATE None of these medicinal products has the indication treatment of inhibitors by immune tolerance induction Medicines with a similar therapeutic aim These are activated factors of prothrombin complex used in patients with anti-factor VIII inhibitors: FEIBA, NOVOSEVEN. 3. ANALYSIS OF AVAILABLE DATA The laboratory submitted 2 studies to support its request as well as a paper published by Orsini et al and a speech given at the annual convention of the French Haematology Society in Efficacy results Retrospective study LFB 1 : A retrospective, non-comparative study analysing the medical reports of children with severe haemophilia A (FVIII <1%), treated for the first time with very-high purity FVIII (FVIII-VHP) between 1988 and The files of 104 severely haemophiliac children (FVIII <1%) were studied. 1 Goudemand J, Rothschild C, Calvez T, Bridey F. A low incidence of high responder inhibitors for the treatment of severe previously untreated patients (PUPs) with haemophilia A with plasma-derived factor VIII product stabilised with von Willebrand factor. Hemophilia. 2004; 10(3): 02P023 (abstract). 3
4 Primary objective: To evaluate the incidence of FVIII inhibitors during FVIII-VHP treatment, in children with severe haemophilia A, previously untreated (naive). Secondary objectives: To investigate the influence of risk factors on this incidence (individual factors, replacement therapy methods); To analyse the inhibitor s progression, and particularly the efficacy of the immune tolerance induction (ITI) treatment using FVIII-VHP in patients with inhibitors. Success criteria for ITI therapy were the following: eradication of the inhibitor validated through inhibitor level <0.6 BU with normal FVIII recovery rate ( 66%) and/or half-life ( 6 hours). Principal inclusion criteria: Children with severe haemophilia A (FVIII <1%), FVIII naive Children whose first replacement therapy was FVIII-VHP during the period from June 1988 to February Endpoints: Percentage of patients developing anti-fviii inhibitor antibodies (level > 0.6 BU) during the course of FVIII-VHP treatment and percentage of strong responder patients ( 5 BU and 10 BU). The period taken into consideration to observe the incidence of inhibitor onset was until development of an inhibitor, or for those not having developed any, until discontinuation of the FVIII-VHP therapy. Results: Principal endpoint Of the 104 children (103 of which were less than 6 years of age), 15 (14.4%) developed an inhibitor after an average of 12 cumulative days of treatment. Of these 15 children: 5 did not modify their treatment regimen (on-demand treatment) and the inhibitors (all of low level <5 BU) spontaneously resolved; 1 died due to the inefficiency of the FVIII treatment; 2 are no longer under FVIII treatment but may potentially return to the activated fractions; 7 received ITI therapy. Secondary endpoint: For one strong responder patient, tolerance induction was partial; in 6 others (3 strong responders and 3 weak responders), the inhibitor disappeared following ITI treatment. 4
5 Post-Marketing Authorisation 2 study (2005 interim report) This safety and efficacy study involved the following coagulation fractions: FACTANE (FVIII), BETAFACT (FIX), WILFACTIN / WILSTART (von Willebrand factor). It began on 20 July Only the results of the first interim analysis (May 2005) are available. The end of the study is scheduled for the 3 rd trimester of To this day, only 4 patients with a constitutional FVIII deficiency and treated with FACTANE have been analysed. ITI treatment was initiated with FACTANE either as a first-line treatment (n=2), or as second-line treatment following failure of recombinant FVIII treatment (n=2). Primary objective: Describe, in particular, the immunological safety of FACTANE based on inhibitor levels and FVIII recovery rates. One of the secondary endpoints is the clinical evaluation of efficacy of FACTANE for immune tolerance induction (ITI) therapy, based on biological evidence (inhibitor level (<0.6 BU), normal recovery rate/half-life of injected FVIII). Table 2: Results: Patients (n = 4) Strong responders (n = 4) Dosage at ITI initiation >100 IU/kg/day (strong dose) ITI Type 1 st line (n = 2) 2 nd line (n = 2) Results - 1 ITI successfully terminated - 1 ITI underway inhibitor - 2 ITI underway inhibitor In 3 out of 4 patients, a decreased inhibitor level was observed, however, these patients can not yet be evaluated as the ITI treatment is still underway. Orsini et al. 3 study This study provides additional retrospective data from 8 other strong responder patients. Seven patients were treated with non-nanofiltered FVIII and 1 patient with FACTANE. Three of these patients are included in the LFB retrospective study. Response to treatment was complete for 5 strong responder patients, obtaining a normal recovery rate ( 66% of theoretical recovery) and/or normal half-life ( 6 hours) and on undetectable inhibitor level (<0.6 BU) Adverse effects In the retrospective study, only data for serious adverse effects leading to death or onset of inhibitors were collected. Three deaths (1 due to septic shock and 2 due to cerebral haemorrhage) and 15 incidences of inhibitor onset were reported. In the post-marketing Authorisation study, no adverse effects were reported in the subpopulation of patients treated with ITI therapy (n=4). 2 Goudemand J, Calvez T, Rothschild C, Négrier C, Grevin JM, Moan AC, Bridey F, Tellier Z et le groupe d'étude FACTEUR VIII-LFB. Etude rétrospective de l'incidence des inhibiteurs "forts répondeurs" du facteur VIII dans l'hémophilie sévère traitée exclusivement par un facteur VIII d'origine plasmatique. Hématologie. 2005; 11 (n hors série): Orsini F, Rothschild C, Beurrier P, et al. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in haemophilia A patients with high-responding inhibitors Haematologica/J Hematol 2005; 90(9):
6 3.3. Conclusion Data from the post-marketing Authorisation are very preliminary as only 17 patients were analysed, 4 of which corresponded to an attempt of immune tolerance induction as 1 st line treatment (2 adults) or as 2 nd line treatment (1 adult and 1 child). The LFB retrospective study, which included 104 patients with severe haemophilia A (<1%) treated with LFB FVIII (non-nanofiltered version), documents the efficacy of inhibitor treatment with the product as ITI therapy (successful in 5 of 6 patients). The results of this retrospective study are corroborated by those of the Orsini et al study, which observed the success of non-nanofiltered FVIII as ITI treatment in 4 other patients and of FACTANE in another, i.e., 5/8 strong responder patients. As FACTANE is produced following an additional stage of viral reduction through nanofiltration to the manufacturing process of FVIII-VHP, the Committee emphasizes that the slight difference between non-nanofiltered FVIII and FACTANE leads to the conclusion that the data obtained with the non-nanofiltered product could be extrapolated. Nevertheless, the studies presented have a very low level of evidence: a small number of patients included and the retrospective character of 2 of these studies. 4. TRANSPARENCY COMMITTEE CONCLUSIONS 4.1. Actual benefit Haemophilia A is a rare and life-threatening disease. FACTANE is intended as curative treatment. The efficacy/adverse effect ratio for this medicinal product is high. This is a first-line treatment in FACTANE induced immune tolerance. There are medicinal alternatives. Public health interest Despite the severity of haemophilia A, the burden of this rare disease is low. Improving management of haemophilia is a necessity falling within the scope of an identified public health priority (GTNDO* and National Plan for Rare Diseases). For patients developing factor VIII inhibitors, the available data do not permit estimation of the impact of FACTANE on morbidity/mortality compared to that of the other existing treatments (in particular NOVOSEVEN and FEIBA). In light of the available information, it is not possible to confidently predict that FACTANE will provide an additional benefit for the identified public health requirement. Consequently, given the current state of knowledge and the other available therapies, it is not expected that the medicinal product FACTANE will have any public health benefit. The actual benefit of FACTANE provided in this indication is substantial. * National Technical Objective Definition Group (DGS-2003) 6
7 4.2. Improvement in actual benefit This medicinal product confirms its place in therapeutic use and represents a useful therapeutic method for ITI treatment in patients developing inhibitors following FACTANE treatment Therapeutic use Haemophilia A is a sex-linked recessive inherited disease, resulting in a more or less severe factor VIII (FVIII) deficiency. Treatment is based on the intake of exogenous plasma-derived or recombinant FVIII concentrate. Onset of anti-fviii antibodies is a complication of haemophilia treatment. These antibodies, commonly known as inhibitors, are antibodies that appear in certain haemophilia A patients in response to FVIII treatment and which neutralise its coagulation action. According to the SPC, human coagulation factor VIII may remain effective in patients who develop, during the course of treatment, a factor VIII inhibitor (neutralising antibody) of low level, less than 5 Bethesda units (BU). Monitoring the factor VIII plasma level ensures that the replacement treatment undertaken is appropriate. The inhibitor level must be measured in order to verify the absence of anamnestic response. In patients with a high inhibitor level, greater than 5 BU, high doses of human coagulation factor VIII may be necessary in order to control severe haemorrhage. In certain cases, in light of the high doses necessary to maintain sufficient factor VIII plasma levels, treatment instauration may be difficult. If haemostasis cannot be obtained with human coagulation factor VIII in the presence of a high inhibitor level, the use of an activated prothrombin complex or an activated factor VIII concentrate may be considered. Such treatments must be administered by physicians with experience in treating patients with haemophilia A. Per the Afssaps recommendations of May , all types of FVIII concentrates are susceptible to successfully induce immune tolerance. However, ITI therapy should preferably be initiated with the FVIII concentrate selected to treat the patient and under which said patient developed the inhibitor (Grade 2C) Target population In France the incidence of haemophilia is approximately 1 in 10,000 births, or 1 in 5,000 male births 5. The prevalence of haemophilia is estimated at approximately 5,000 patients, of which approximately 80% present haemophilia A, i.e., approximately 4,000 patients. In France, according to the FranceCoag 6 cohort, the prevalence of inhibitors is estimated at 6%. This indicates that approximately 200 patients have inhibitors. 4 Afssaps. Développement d inhibiteurs et prise en charge chez les patients hémophiles traités par facteur VIII ou IX d origine plasmatique ou recombinante. 15 mai Sultan Y. L hémophile A et B. Encyclopédie Orphanet Accessible at 6 Institut de veille sanitaire. Réseau France Coag. Accessible at 7
8 According to specialist opinion, not all these patients would benefit from FACTANE ITI treatment, in particular: - Paediatric and adult patients with little bleeding: on-demand treatment with activated fractions - Children and families for whom observance of ITI protocol, an intensive dose or activated fraction prophylactic treatment is not envisaged. - Children who have received only recombinant factor VIII until onset of the inhibitor and in whom it is logical to initiate a recombinant ITI treatment. - Patients having developed inhibitors under a FVIII other than FACTANE, as it is recommended that ITI treatment be initiated with the same FVIII concentrate selected to treat the patient and under which the patient developed the inhibitor Transparency Committee recommendations The Transparency Committee recommends inclusion on the list of medicines approved for use by hospitals and various public services in the indication Human coagulation factor VIII is indicated for the treatment of inhibitors by immune tolerance induction (ITI). 8
Opinion 2 April 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 2 April 2014 NOVOEIGHT 250 IU, powder and solvent for solution for injection B/1 vial of powder + 1 prefilled syringe
More informationTRANSPARENCY COMMITTEE OPINION. 10 March 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 March 2010 FIBROGAMMIN 62.5 U/ml, powder and solvent for injection or infusion B/1 Powder in vial + 4 ml of solvent
More informationFactane : from product characteristics to clinical efficiency The experience in immune tolerance induction
Factane : from product characteristics to clinical efficiency The experience in immune tolerance induction Prof. Benoît POLACK, MD, PhD University Hospital - Grenoble, France CNRS UJF UMR 5525 Adana, May
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 April 2008 YONDELIS 0.25 mg, vial containing powder for concentrate for solution for infusion Box containing 1 vial
More informationClinical Commissioning Policy: Immune Tolerance Induction (ITI) for haemophilia A (all ages)
Clinical Commissioning Policy: Immune Tolerance Induction (ITI) for haemophilia A (all ages) Reference: NHS England: 16042/P NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationMedication Prior Authorization Form
Section I Member Information Name (Last, First, Middle Initial) Date of Birth WEA Trust Subscriber Number Diagnosis Page 2 1. MEDICATION 2. STRENGTH 3. DIRECTIONS 4. QUANTITY FEIBA NF NovoSeven RT HEMOFIL
More informationPLEASE REFER TO UKHCDO WEBSITE TO ENSURE YOU ARE USING THE MOST RECENT VERSION OF THIS PROTOCOL
PLEASE REFER TO UKHCDO WEBSITE TO ENSURE YOU ARE USING THE MOST RECENT VERSION OF THIS PROTOCOL http://www.ukhcdo.org UKHCDO protocol for first line immune tolerance induction for children with severe
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 February 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 February 2010 ADIXONE 50 µg, tablet Box of 30 (CIP: 390 604.3) Box of 60 (CIP: 390 606.6) Box of 90 (CIP: 390 607.2)
More informationSummary of the risk management plan (RMP) for Elocta (efmoroctocog alfa)
EMA/707623/2015 Summary of the risk management plan (RMP) for Elocta (efmoroctocog alfa) This is a summary of the risk management plan (RMP) for Elocta, which details the measures to be taken in order
More informationFactor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate. From: European Plasma Fractionation Association (EPFA)
Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: European Plasma Fractionation Association (EPFA) 1. Summary
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05.01.16 Last Review Date: 02.19 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important Reminder at
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 20 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 February 2008 DUROGESIC 12 micrograms/hour (2.1 mg/5.25 cm²), transdermal patch Box of 5 sachets (CIP: 369 851-5)
More informationCoding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05.01.16 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05.01.16 Last Review Date: 02.19 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important Reminder at
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 June 2012 TARCEVA 25 mg, film-coated tablet B/30 (CIP code: 369 232 3) TARCEVA 100 mg, film-coated tablet B/30 (CIP
More informationInhibitors in Patients With Hemophilia Elena Santagostino MD, PhD
Inhibitors in Patients With Hemophilia Elena Santagostino MD, PhD Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione Ca Granda - Ospedale Maggiore Policlinico and University of Milan Milan,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 VIRAFERONPEG 50 µg/ 0.5 ml powder and solvent for injectable solution Pack of 1 (CIP: 355 189.3)
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationHemofílie. MUDr.Ivan Vonke, MBA OKH, Nemocnice České Budějovice, a.s.
Hemofílie e MUDr.Ivan Vonke, MBA OKH, Nemocnice České Budějovice, a.s. Hemophilia Incidence: Hemopilia A (deficiency of factor VIII): 1-2 of 10 000 male newborns in all ethnic groups Hemophilia B (deficiency
More informationExperience with a third generation recombinant factor VIII concentrate (Advate Ò ) for immune tolerance induction in patients with haemophilia A
Haemophilia (2009), 15, 718 726 DOI: 10.1111/j.1365-2516.2008.01960.x ORIGINAL ARTICLE Inhibitors Experience with a third generation recombinant factor VIII concentrate (Advate Ò ) for immune tolerance
More informationTRANSPARENCY COMMITTE OPINION. 19 December 2007
The legally binding text is the original French version TRANSPARENCY COMMITTE OPINION 19 December 2007 ATRIANCE 5 mg/ml, Solution for Infusion Pack of 6 vials (571 348-9) Applicant: GlaxoSmithKline nelarabine
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 REBETOL 200 mg capsules Pack of 84 (CIP code: 351 971.9) Pack of 112 (CIP code: 373 277.8) Pack of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 MOZOBIL 20 mg/ml, solution for injection Box containing 1 vial (CIP: 397 153-7) Applicant: GENZYME
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT KOGENATE Bayer 250 IU powder and solvent for solution for injection KOGENATE Bayer 500 IU powder and solvent for solution for
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Clotting Factors and Antithrombin Effective Date... 4/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 8007 Table of Contents Coverage Policy...
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 December 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 December 2007 METHADONE AP-HP 1mg, gelatin-coated capsule Box of 7 (CIP: 379 146-2) METHADONE AP-HP 5mg, gelatin-coated
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fanhdi 25 IU/ml powder and solvent for solution for injection. Fanhdi 50 IU/ml powder and solvent for solution for injection. Fanhdi
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Human - Alphanate, Humate-P, Wilate) Reference Number: ERX.SPA.185 Effective Date: 01.11.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 17 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 17 November 2010 MEPACT 4 mg, powder for suspension for infusion B/1 (CIP code: 398331 6) Applicant : IDM PHARMA S.A.S
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 January 2007 DICLOFENAC SODIUM MIKA PHARMA 4%, skin spray solution 7.5 g Vial (CIP: 362 261-8) 12.5 g Vial (CIP:
More informationOpinion 23 July 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 ACADIONE 250 mg, sugar-coated tablet Bottle of 120 (CIP: 34009 329 390 7 7) Applicant: SANOFI-AVENTIS
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Willebrand Factor Complex (Human - Alphanate, Humate-P, Wilate) Reference Number: ERX.SPA.185 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationThe role of plasma products in the treatment of haemophila today. Scott Dunkley Haemophilia and Thrombosis Unit Royal Prince Alfred Hospital Sydney
The role of plasma products in the treatment of haemophila today Scott Dunkley Haemophilia and Thrombosis Unit Royal Prince Alfred Hospital Sydney Inhibitors remain the greatest challenge to haemophilia
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationBlood products and plasma substitutes
Blood products and plasma substitutes Plasma substitutes Dextran 70 and polygeline are macromolecular substances which are metabolized slowly; they may be used to expand and maintain blood volume in shock
More informationAfstyla. (antihemophilic factor [recombinant] single chain) New Product Slideshow
Afstyla (antihemophilic factor [recombinant] single chain) New Product Slideshow Introduction Brand name: Afstyla Generic name: Antihemophilic Factor (recombinant), single chain Pharmacological class:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 CARDENSIEL 1.25 mg, film-coated tablet B/30 (CIP code: 352 968-1) CARDENSIEL 2.5 mg, film-coated tablet
More informationTRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 ERBITUX 2 mg/ml, Solution for infusion 1 bottle of 50 ml (CIP: 565 806 9) Applicant : MERCK LIPHA
More informationSession 1 : Fibrinogen deficiencies
13 th Workshop on Thrombosis and Paediatric Haemostasis Marseille, 13 th October 2010 Session 1 : Fibrinogen deficiencies Clinical, biological and therapeutic concerns : P De Moerloose, Geneva Genetic
More informationTRANSPARENCY COMMITTEE. Opinion. 29 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 November 2006 HEXATRIONE 2% suspension for injection (intra-articular) Box containing one 2-ml vial - CIP code:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Willebrand Factor Complex (Human - Alphanate, Humate-P, Wilate) Reference Number: ERX.SPA.185 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationTRANSPARENCY COMMITTEE. The legally binding text is the original French version OPINION. 21 June 2006
TRANSPARENCY COMMITTEE The legally binding text is the original French version OPINION 21 June 2006 Granocyte 13 (13.4 million IU/1 ml), powder and solvent in prefilled syringe for solution for injection
More informationTRANSPARENCY COMMITTEE OPINION. 13 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 January 2010 XOLAIR 150 mg, powder and solvent for solution for injection Box containing 1 x 150 mg vial + 1 x
More informationHemlibra (emicizumab-kxwh) NEW PRODUCT SLIDESHOW
Hemlibra (emicizumab-kxwh) NEW PRODUCT SLIDESHOW Introduction Brand name: Hemlibra Generic name: Emicizumab-kxwh Pharmacological class: Bispecific factor IXa- and factor X-directed antibody Strength and
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 Review of the dossier of the proprietary drugs included on the list of reimbursable medicines for a
More informationThe First rfviii WITH A PROLONGED HALF-LIFE
Visit ELOCTATEpro.com for more information The First rfviii WITH A PROLONGED HALF-LIFE Indications ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is a recombinant DNA derived, antihemophilic
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 October 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 October 2011 PEDIAVEN AP-HP G15, solution for infusion 1000 ml of solution in two chamber bag, B/4 (CIP code: 419
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 CHLORAMINOPHENE 2 mg, capsule B/30 (CIP code: 3369906) Applicant: TECHNI-PHARMA chlorambucil ATC code:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 PREZISTA 400 mg, film-coated tablet B/60 (CIP code: 393 138-3) Applicant: JANSSEN-CILAG darunavir
More informationDATA SHEET. KOGENATE FS (with vial adapter) octocog alfa (bhk) (recombinant Factor VIII) NAME OF THE MEDICINE
DATA SHEET KOGENATE FS (with vial adapter) octocog alfa (bhk) (recombinant Factor VIII) NAME OF THE MEDICINE KOGENATE FS 250 IU KOGENATE FS 500 IU KOGENATE FS 1000 IU KOGENATE FS 2000 IU KOGENATE FS 3000
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 VELMETIA 50 mg/850 mg, film-coated tablets B/56 (CIP code: 386 778-0) VELMETIA 50 mg/1 000 mg, film-coated
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN PROTHROMBIN COMPLEX PRODUCTS (CPMP/BPWG/3735/02)
European Medicines Agency Human Medicines Evaluation Unit London, 21 October 2004 Corrigendum, 18 November 2004 CPMP/BPWG/3735/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN
More informationSocial Values and Health Priority Setting Case Study
Social Values and Health Priority Setting Case Study Title of Case Study Author Author Contact Novo Seven in haemophilia: clinical decision making and funding policies in Germany Author: Dr Alena Buyx,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 January 2012 EPIDUO, gel Tube of 30 g (CIP code: 383 814-6) Tube of 60 g (CIP code: 383 816-9) Applicant: GALDERMA
More informationHemophilia: diagnostics and treatment
Hemophilia: diagnostics and treatment Eveline Mauser-Bunschoten Van Creveldkliniek department of benign hematology thrombosis and hemostasis What is hemophilia? Hemophilia A: deficiency of factor VIII
More informationTRANSPARENCY COMMITTEE OPINION. 28 April 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 April 2010 ENCEPUR 1.5 µg / 0.5 ml, suspension for injection in prefilled syringe. Tick-borne encephalitis vaccine
More informationThe legally binding text is the original French version. Opinion 28 May Hospital use (French Social Security Code L )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 28 May 2014 ADASUVE 9.1 mg, inhalation powder, pre-dispensed B/5 (CIP: 3400958597671) Applicant: BIOPROJET PHARMA
More informationCoagulopathy Case - 3. Andy Nguyen, M.D. 2009
Coagulopathy Case - 3 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 21 year-old male seen in the emergency room with a swollen, tender right knee. Patient is an electrician who had fallen to the ground an
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 RELISTOR 12 mg/0.6 ml solution for injection 1 vial (CIP: 387 365-1) 2 vials + 2 sterile syringes
More informationContents 1 Bleeding disorders Haemophilia... 12
Contents 1 Bleeding disorders... 5 1.1 Features of a bleeding disorder... 5 1.2 First line diagnostic investigations... 5 1.2.1 Clotting screens... 6 1.3 Further investigations... 6 1.3.1 Investigation
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationTRANSPARENCY COMMITTEE OPINION. 4 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 March 2009 MENCEVAX powder and solvent for solution for injection Meningococcal polysaccharide vaccine for serogroups
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationHaematology Subcommittee of PTAC Meeting held 16 March 2016
Haematology Subcommittee of PTAC Meeting held 16 March 2016 (minutes for web publishing) The Haematology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationHaemophilia Suspected Bleed
Haemophilia Suspected Bleed Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Guideline for the management
More informationOpinion 18 December 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 LANTUS 100 units/ml, solution for injection in a vial B/1 vial of 10 ml (CIP: 34009 359 464 9 2)
More informationTRANSPARENCY COMMITTEE OPINION. 21 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 January 2009 BRIDION 100 mg/ml, solution for injection Box containing 10 x 2 ml bottles, CIP: 573 553-9 Box containing
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 11 April 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 11 April 2012 XGEVA 120 mg, solution for injection 1 glass vial of 120 mg/1.7 ml (CIP code: 217 253-8) 4 glass vials
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 REMOVAB 10 microgram concentrate for infusion solution Carton containing 1 pre-filled syringe (CIP:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Wilate 500, 500 IU VWF/500 IUFVIII, powder and solvent for solution for injection Wilate 1000, 1000 IU VWF/1000 IUFVIII, powder and solvent
More informationDATA SHEET. KOGENATE FS (with BIO-SET) octocog alfa (bhk) (recombinant Factor VIII) NAME OF THE MEDICINE
DATA SHEET KOGENATE FS (with BIO-SET) octocog alfa (bhk) (recombinant Factor VIII) NAME OF THE MEDICINE KOGENATE FS 250 IU KOGENATE FS 500 IU KOGENATE FS 1000 IU KOGENATE FS 2000 IU KOGENATE FS 3000 IU
More informationHEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS
HEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS Media Inquiries: (650) 467-6800 About Hemlibra Hemlibra (emicizumab-kxwh) is approved by the FDA as a prophylactic (preventative)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 ANAPEN 0.50 mg/0.3 ml, solution for injection in pre-filled syringe 1 pre-filled syringe (glass), box of
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2007 RECTOGESIC 4 mg/g, rectal ointment B/1 (CIP 376 537-0) Applicant : PROSTRAKAN PHARMA SAS Glyceryl trinitrate
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationEuropean Medicines Agency decision
EMA/585994/2013 P/0270/2013 of 30 October 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for eptacog alfa (activated) (EMEA-001382-PIP01-12) in accordance with
More informationTRANSPARENCY COMMITTEE OPINION. 4 November 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 November 2009 RANEXA 375 mg extended release tablet Pack of 60 (CIP: 394 370-7) RANEXA 500 mg extended release tablet
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 4 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 January 2012 VOTUBIA 2.5 mg, tablet B/30 (CIP code: 219 475-8) VOTUBIA 5 mg, tablet B/30 (CIP code: 219 476-4) Applicant:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationDATA SHEET XYNTHA. moroctocog alfa (rch) (recombinant coagulation factor VIII)
DATA SHEET XYNTHA moroctocog alfa (rch) (recombinant coagulation factor VIII) NAME OF THE MEDICINE XYNTHA moroctocog alfa (rch) 250, 500, 1000, 2000 IU powder for injection vial. XYNTHA moroctocog alfa
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 GRAZAX 75 000 SQ-T, oral lyophilisate B/30 (CIP: 378 011-6) B/100 (CIP code: 378 012-2) B/90 (CIP code:
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document - Oral Drugs requiring prior authorization: the list of drugs requiring prior
More informationNew Clinical Results with Fitusiran
Venkat Living with Hemophilia New Clinical Results with Fitusiran 2017 International Society on Thrombosis and Haemostasis (ISTH) Congress July 10, 2017 Agenda Welcome Christine Lindenboom Vice President,
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 NAME OF THE MEDICINAL PRODUCT Wilate 450, 450 IU FVIII/400 IU VWF, powder and solvent for solution for injection Wilate 900, 900 IU FVIII/800 IU VWF, powder and solvent for solution for injection 2 QUALITATIVE
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationOpinion 15 May ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/10 (CIP: )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/10 (CIP: 34009 563 619 7 7) Applicant:
More informationOpinion 23 July 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 IMUREL 50 mg, film-coated tablet (B/100) (CIP: 34009 364 149 0 7) IMUREL 25 mg, film-coated tablet (B/50)
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationClinical Commissioning Policy: Human coagulation factor X for hereditary factor X deficiency (all ages)
Clinical Commissioning Policy: Human coagulation factor X for hereditary factor X deficiency (all ages) NHS England Reference: 170105P 1 NHS England INFORMATION READER BOX Directorate Medical Operations
More information